医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LCT’s NTCELL® Parkinson’s Trial Results to Be Presented in Berlin

2016年06月23日 PM03:25
このエントリーをはてなブックマークに追加


 

SYDNEY & AUCKLAND, New Zealand

As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled “Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up” takes place at 12 noon Berlin time today.

Dr Snow, Principal Investigator for the trial, said, “This data shows a striking and significant improvement in all measurements of Parkinson’s disease in the four patients. Everything we measured has improved.”

Dr Ken Taylor, CEO of LCT, said, “The results of this clinical trial are consistent with what LCT has found in pre-clinical studies. Moreover microarray analyses identified that several nerve growth factors and nerve protective agents are released from NTCELL and this may explain the improvement observed in all of the measurements of Parkinson’s disease.”

The poster is available to view here.

For further information: www.lctglobal.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160622006576/en/

CONTACT

At the Company:
Ken Taylor, +64 9 276 2690
Chief
Executive
Mobile: +64 21 796 000
ktaylor@lctglobal.com
or
Media
Contact:

Botica Butler Raudon Partners
Rachael Joel, +64 9
303 3862
Mobile: +64 21 403 504
rachaelj@botica.co.nz

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Amway in Association With Kony Hosted First-Ever Hackathon to Advance Digital Transformation in the Industry
  • 22ndセンチュリーはFDAのニコチン低減計画が直ちに実行可能であると発表
  • Emmaus Life Sciences宣布《新英格兰医学杂志》发表 Endari™(左旋谷氨酰胺口服粉剂)治疗镰状细胞病3期试验结果
  • Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital
  • Dr. Reddy’s Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market